PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells

Platinum compounds are the foundation of chemotherapy regimens for non-small cell lung cancer (NSCLC) despite poor response rates and limited response duration. It has been reported that tumor expression of excision repair cross-complementation group 1 (ERCC1), a key component in nucleotide excision...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Cheng, Haiying, Zhang, Zhenfeng, Borczuk, Alain, Powell, Charles A., Balajee, Adayabalam S., Lieberman, Howard B., Halmos, Balazs
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2013
Témata:
Original Manuscript
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3616665/
https://ncbi.nlm.nih.gov/pubmed/23275151
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/carcin/bgs393
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky